Select Language

TrkC

TrkC Overview

English Name	Neurotrophic tyrosine kinase receptor type 3	Approved Drugs	4
Drugs in Clinical Trials	6	Target Synonym	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
Highest Development Stage	Approved

English Name	Neurotrophic tyrosine kinase receptor type 3
Target Synonym	NT-3 growth factor receptor，TrkC tyrosine kinase，Neurotrophic Receptor Tyrosine Kinase 3，Neurotrophic Tyrosine Kinase， Receptor， Type 3，EC:2.7.10.1，GP145-TrkC，TRKC，EC 2.7.10，ETS Related Protein-Neurotrophic Receptor Tyrosine Kinase Fusion Protein，Neurotrophic Tyrosine Kinase Receptor Type 3，Tyrosine Kinase Receptor C，ETV6-NTRK3 Fusion，Trk-C，NTRK3，Gp145(TrkC)，EC 2.7.10.1，Receptor， trkC
Approved Drugs	4
Drugs in Clinical Trials	6
Highest Development Stage	Approved

TrkC Product List

Product Category
Protein (1)Cell (1)
Product Status
Launched (2)
Species
Human (2)
Tag
Fc Tag (1)Tag Free (1)
Conjugate
Unconjugated (1)- (1)

Cat. No.	Species	Host	Product Description	Structure	Purity	Feature
CHEK-ATP189	Human	HEK293	HEK293/Human TrkC Stable Cell Line
TRC-H5256	Human	HEK293	Human TrkC / NTRK3 Protein, Fc Tag (MALS verified)

Total: 2

TrkC Background

Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene. It belongs to the tropomyosin-related kinase (Trk) family of receptor tyrosine kinases (TrkA, TrkB, and TrkC). TrkC is the high affinity catalytic receptor for the neurotrophin NT-3 (neurotrophin-3). As such, TrkC mediates the multiple effects of this neurotrophic factor, which includes neuronal differentiation and survival.

TrkC Synonyms

NT-3 growth factor receptor,GP145-TrkC,Neurotrophic tyrosine kinase receptor type 3, TrkC tyrosine kinase

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Lestaurtinib	SPM-924; A-154475.0; KT-5555; SP-924; CEP-701	Phase 3 Clinical	Kyowa Hakko Kirin Co Ltd	Bone Marrow Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neuroblastoma; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Prostatic Neoplasms; Psoriasis; Thrombocythemia, Essential	Details
Merestinib	5OGS5K699E; LY-2801653	Phase 2 Clinical	Eli Lilly And Company	Biliary Tract Neoplasms; Bone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Microsatellite instability-high cancer; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours	Details
FCN-011	FCN-011	Phase 2 Clinical		Solid tumours	Details
Emzeltrectinib	CT-3417; TQB-3558	Phase 1 Clinical	Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd	Solid tumours	Details
HG-030	HG-030	Phase 1 Clinical	Hitgen Inc	Solid tumours	Details
Paltimatrectinib	PBI-200	Phase 1 Clinical	Pyramid Biosciences	Brain Neoplasms; Desmoplastic Small Round Cell Tumor; Solid tumours	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Taletrectinib Adipate	DS-6051b; DS-6051a; DS-6051; AB-106; IBI-344	Approved	Daiichi Sankyo Co Ltd	达伯乐, DOVBLERON, IBTROZI	Mainland China	Carcinoma, Non-Small-Cell Lung	AnHeart Therapeutics Co Ltd	2024-12-17	Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Neoplasms; Solid tumours	Details
Entrectinib	NMS-E628; RXDX-101; RG-6268	Approved	Nerviano Medical Sciences Srl	Rozlytrek, 罗圣全	Japan	Carcinoma, Non-Small-Cell Lung	Chugai Pharmaceutical Co Ltd	2019-06-18	Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Melanoma; Neoplasms; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Sarcoma; Solid tumours; Thyroid Cancer, Papillary	Details
Larotrectinib sulfate	LOXO-101; ARRY-470; BAY-2757556	Approved	Array Biopharma	Vitrakvi, 维泰凯	United States	Solid tumours	Bayer Healthcare	2018-11-26	Breast Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Ependymoma; Esophageal Neoplasms; Fibrosarcoma; Glioma; Head and Neck Neoplasms; Hematologic Neoplasms; Hepatoblastoma; Histiocytic Sarcoma; Histiocytosis, Langerhans-Cell; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Medulloblastoma; Melanoma; Multiple Myeloma; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thyroid Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms; Wilms Tumor; Xanthogranuloma, Juvenile	Details
Repotrectinib	TPX-0005; BMS-986472; ZL-2308	Approved	Turning Point Therapeutics Inc	Augtyro, 奥凯乐	United States	Carcinoma, Non-Small-Cell Lung	Bristol-Myers Squibb Company	2023-11-15	Brain metastases; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Hepatic Insufficiency; Lymphoma; Neoplasms; Solid tumours	Details